Powered by the NEXT Committee
Bassetti M. et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. The Lancet Infectious Disease, 21(2):226-240 (2021). doi: 10.1016/S1473-3099(20)30796-9.
NEXT is a Steering Committee that speaks on behalf of trainees/young specialists and helps shape the future of the European Society of Intensive Care Medicine (ESICM) and of the discipline. Would you like to join us? Visit https://www.esicm.org/the-esicm/membership/ and follow us on Facebook | Twitter | Instagram.
Disclaimer: This visual abstract was created because the original publication from which it is derived was judged to be relevant in the field of Intensive Care Medicine. The original publication is available for full consultation at the journal’s website. The creator is not related in any way to the original publication.